Market Overview

Cellectis extends its TAL technology intellectual property portfolio through the acquisition of two exclusive licenses from Iowa State University


Regulatory News:

Cellectis (Alternext: ALCLS), the genome engineering specialist, announces that it has signed two exclusive license agreements with the Iowa State University that grant Cellectis the worldwide right to use inventions related to TAL effector-nucleases (TALENsTM) and monomeric TALENsTM.

These two exclusive licenses granted to Cellectis cover all uses of the TAL technologies in any field. TALENsTM are revolutionary new tools for genome engineering, which allow a more efficient and targeted ways for DNA recognition and cleavage, in any genome of any species. This technology has broad applications in genome engineering including fundamental genetic research, crop improvement, and treatment of human genetic diseases.

Cellectis has already integrated TAL effector nucleases into its DNA Nuclease production platform. TAL effector nucleases are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest, in any species. Cellectis is able to produce TAL nucleases in around one week, providing customers with rapid access to custom-made products.

“Cellectis strengthens its leading position in the genome engineering arena,” stated André Choulika, CEO of Cellectis. “Cellectis' R&D teams are already applying these technologies for our programs and we are extending our offerings to a wider range of innovative first-in-class services and research reagents based on it.”

About Cellectis

Founded in France in 1999, the Cellectis Group is based on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Co-created by André Choulika, its Chief Executive Officer, Cellectis is today one of the world leading companies in the field of genome engineering. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States. Cellectis achieved revenues of €16M in 2011 and has since its inception has signed more than 80 industrial agreements with pharmaceutical, agrochemical, and biotechnology companies. AFM, DuPont, BASF, Bayer, Total, Limagrain, and Novo Nordisk are some of the Group's clients and partners.

Since 2007, Cellectis has been listed on NYSE-Euronext Alternext market (code: ALCLS) in Paris. For more information, visit our website:

About Iowa State University

Chartered in 1858, Iowa State University of Science and Technology is working to integrate basic research, new technologies, and entrepreneurial applications to meet the challenges of the 21st century. Iowa State University is located in Ames, Iowa, USA and currently has more than 31,000 students. More information about university research and technology transfer is available at


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
Profile PR
Leslie Boutin / Hina de Soultrait
Tel: +33 (0)1 56 26 72 00

View Comments and Join the Discussion!